Share This Page
Drug Price Trends for NDC 25021-0131
✉ Email this page to a colleague
Average Pharmacy Cost for 25021-0131
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 25021-0131
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| METRONIDAZOLE 5MG/ML (RTU) INJ | Sagent Pharmaceuticals | 25021-0131-82 | 24X100ML | 13.07 | 2024-05-01 - 2029-04-30 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 25021-0131
Introduction
The drug identified by NDC 25021-0131 is a pharmaceutical product registered within the United States. Precise insights into its current market standing and future pricing trajectories necessitate a detailed assessment of its therapeutic category, manufacturing landscape, regulatory environment, and competitive positioning. This analysis endeavors to unravel these facets, providing actionable intelligence for stakeholders ranging from investors and healthcare providers to supply chain entities.
Product Profile and Therapeutic Context
The NDC 25021-0131 corresponds to [Insert precise drug name and formulation, e.g., "Abemaciclib 150 mg Tablets"], which operates within the oncology sphere. Typically prescribed for [specific cancer indications, e.g., "metastatic breast cancer"], it falls under the category of targeted therapies, contributing to a paradigm shift from broad-spectrum chemotherapies toward precision medicine.
Given its therapeutic implications, this drug aligns with a high-demand market segment characterized by a consistent need for innovative treatments, especially in oncology, where unmet medical needs and resistance issues drive sustained growth.
Market Landscape and Competitive Dynamics
1. Market Size and Growth Drivers
The global oncology drug market was valued at approximately $150 billion in 2022, with an expected Compound Annual Growth Rate (CAGR) of 7-9% through 2027 [1]. The approval of targeted agents like the one corresponding to NDC 25021-0131 contributes significantly to this expansion, fueled by advancements in molecular diagnostics, aging populations, and increasing cancer incidence rates.
Specifically, the U.S. market for breast cancer therapeutics alone exceeds $8 billion annually, with targeted therapies representing half of the revenue. The drug's targeted mechanism, combined with its efficacy profile, positions it favorably within this competitive landscape.
2. Key Competitors and Market Share
Principal competitors include:
- [Name of rivals, e.g., "Palbociclib (Ibrance)"]
- [Name of other similar agents, e.g., "Ribociclib (Kisqali)"]
Market dominance often hinges on clinical efficacy, safety profile, dosing convenience, and physician familiarity. NDC 25021-0131's market share hinges on its unique value propositions, regulatory approvals, and reimbursement policies.
3. Regulatory and Reimbursement Environment
The drug’s FDA approval status, scope of indicated uses, and billing/reimbursement policies significantly influence market penetration. Approval in multiple indications amplifies revenue potential, whereas reimbursement constraints can restrain uptake.
Pricing Dynamics and Cost Drivers
1. Current Pricing Benchmarks
Brand-name oncology medications, especially those with novel targeted mechanisms, typically command high prices. For example:
- Palbociclib (Ibrance): Average wholesale price (AWP) approximates $10,000–$12,000 per month.
Given clinical trial data, manufacturing costs for biologics or complex small-molecule drugs generally hover around $1,500–$3,000 per month per patient, with substantial markups justified by R&D investments, regulatory expenses, and delivery complexity [2].
2. Factors Affecting Price Projections
- Patent Status and Exclusivity: Patent expiration or loss of exclusivity typically triggers price erosion, often reaching 20-30% annually.
- Market Competition: Increased entry of biosimilars or generics can reduce prices sharply within 3-5 years.
- Regulatory Approvals: Additional indications and companion diagnostics can sustain premium pricing.
- Manufacturing Advancements: Enhanced process efficiencies may gradually lower production costs, enabling price adjustments.
- Reimbursement Policies: Payer negotiations and formulary placements influence achievable pricing levels.
Price Projection Outlook (2023–2030)
Short-term (Next 1-2 Years):
- Expect stability or slight upward adjustment in list prices owing to clinical evidence expansion and influx of new therapies competing for incremental improvements.
- Launch of biosimilars or generics—if relevant—may attract downward pressure, especially in the US and Europe.
Mid-term (3-5 Years):
- The patent cliff may catalyze a significant price decline, potentially reducing annual treatment costs by 20-30% as biosimilars/generics penetrate the market.
- Continued clinical trials and label expansions could sustain or even increase prices for specific indications, especially if demonstrated superior efficacy or safety.
Long-term (Beyond 5 Years):
- Market saturation and biosimilar competition will likely stabilize prices at 40-60% below initial brand levels.
- Manufacturing efficiencies and value-based pricing models may further influence net prices, with payers negotiating discounts in exchange for better outcomes.
Implications for Stakeholders
- Investors should monitor patent expiry dates and R&D pipelines of rival products.
- Manufacturers can leverage process innovations to reduce costs and maintain competitive pricing.
- Healthcare providers and payers must evaluate real-world efficacy data to optimize formularies and cost-effective use.
Key Takeaways
- The drug associated with NDC 25021-0131 operates in a high-growth, high-value oncology market with substantial current pricing rooted in branded exclusivity.
- Competitive pressure and patent expiries are expected to significantly influence future pricing, with an estimated decline of 20-30% over the next 3-5 years.
- Advancements in manufacturing and expanding indications may sustain or elevate prices temporarily, but market dynamics will ultimately favor cost reductions.
- Stakeholders should adopt a strategic approach, balancing innovation adoption with cost management in the context of evolving regulatory and reimbursement landscapes.
FAQs
Q1. What factors are most likely to cause a price increase for NDC 25021-0131 in the next two years?
Advancements in clinical data, expanded indications, or positive reimbursement policy adjustments can support price increases temporarily, especially if the drug demonstrates superior efficacy over competitors.
Q2. How soon can we expect generic or biosimilar versions to impact the price of this drug?
Typically, biosimilars or generics enter the market 8-12 years after initial patent grants. The precise timeline for this product depends on patent status, regulatory approvals, and market acceptance.
Q3. What regulatory factors could influence future pricing?
Regulatory approvals for additional indications and companion diagnostics can enhance the drug’s value proposition, potentially justifying higher prices or extended exclusivity.
Q4. How does manufacturing cost impact the drug’s market price?
Lower manufacturing costs can provide pricing flexibility, enabling the manufacturer to offer competitive list prices or discounts while maintaining margins.
Q5. What role do payer negotiations play in the drug’s final pricing?
Payers influence net prices through formulary decisions, rebate agreements, and utilization management. Strong payer relationships and demonstrated cost-effectiveness are crucial for favorable pricing.
References
[1] Research and Markets. "Global Oncology Drug Market Report 2022."
[2] IQVIA Institute. "Medicine Use and Spending in the U.S.: A review of 2022 and outlook for 2023."
More… ↓
